NASDAQ · SOPH
SOPHiA GENETICS SA financials
$8.30−2.24%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Dec 31 | Q4 '24 Dec 31 | Q4 '23 Dec 31 | Q4 '22 Dec 31 | Q4 '21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Diluted EPS | — | — | — | — | — |
| EBITDA | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating cash flow | — | — | — | — | — |
| Free cash flow | — | — | — | — | — |
| Diluted shares | 67.5M | 66.1M | 64.8M | 64.1M | 55.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $70.3M | $80.2M | $123.3M | $161.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $47.7M | $13.2M | $0.00 | $0.00 |
| Total assets | $163.0M | $155.3M | $206.2M | $243.8M |
| Total liabilities | $115.9M | $58.8M | $54.7M | $43.7M |
| Shareholders' equity | $47.1M | $96.5M | $151.4M | $200.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology